Psychedelics in developmental stuttering to modulate brain functioning: a new therapeutic perspective?

Developmental stuttering (DS) is a neurodevelopmental speech-motor disorder characterized by symptoms such as blocks, repetitions, and prolongations. Persistent DS often has a significant negative impact on quality of life, and interventions for it have limited efficacy. Herein, we briefly review ex...

Full description

Bibliographic Details
Main Authors: Pasculli, G, Busan, P, Jackson, ES, Alm, PA, De Gregorio, D, Maguire, GA, Goodwin, GM, Gobbi, G, Erritzoe, D, Carhart-Harris, RL
Format: Journal article
Language:English
Published: Frontiers Media 2024
_version_ 1811140057909690368
author Pasculli, G
Busan, P
Jackson, ES
Alm, PA
De Gregorio, D
Maguire, GA
Goodwin, GM
Gobbi, G
Erritzoe, D
Carhart-Harris, RL
author_facet Pasculli, G
Busan, P
Jackson, ES
Alm, PA
De Gregorio, D
Maguire, GA
Goodwin, GM
Gobbi, G
Erritzoe, D
Carhart-Harris, RL
author_sort Pasculli, G
collection OXFORD
description Developmental stuttering (DS) is a neurodevelopmental speech-motor disorder characterized by symptoms such as blocks, repetitions, and prolongations. Persistent DS often has a significant negative impact on quality of life, and interventions for it have limited efficacy. Herein, we briefly review existing research on the neurophysiological underpinnings of DS -specifically, brain metabolic and default mode/social-cognitive networks (DMN/SCN) anomalies- arguing that psychedelic compounds might be considered and investigated (e.g., in randomized clinical trials) for treatment of DS. The neural background of DS is likely to be heterogeneous, and some contribution from genetically determinants of metabolic deficiencies in the basal ganglia and speech-motor cortical regions are thought to play a role in appearance of DS symptoms, which possibly results in a cascade of events contributing to impairments in speech-motor execution. In persistent DS, the difficulties of speech are often linked to a series of associated aspects such as social anxiety and social avoidance. In this context, the SCN and DMN (also influencing a series of fronto-parietal, somato-motor, and attentional networks) may have a role in worsening dysfluencies. Interestingly, brain metabolism and SCN/DMN connectivity can be modified by psychedelics, which have been shown to improve clinical evidence of some psychiatric conditions (e.g., depression, post-traumatic stress disorder, etc.) associated with psychological constructs such as rumination and social anxiety, which also tend to be present in persistent DS. To date, while there have been no controlled trials on the effects of psychedelics in DS, anecdotal evidence suggests that these agents may have beneficial effects on stuttering and its associated characteristics. We suggest that psychedelics warrant investigation in DS.
first_indexed 2024-09-25T04:15:56Z
format Journal article
id oxford-uuid:b2692970-e913-4f70-8d5b-1da7f3cfe717
institution University of Oxford
language English
last_indexed 2024-09-25T04:15:56Z
publishDate 2024
publisher Frontiers Media
record_format dspace
spelling oxford-uuid:b2692970-e913-4f70-8d5b-1da7f3cfe7172024-07-17T20:03:46ZPsychedelics in developmental stuttering to modulate brain functioning: a new therapeutic perspective?Journal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:b2692970-e913-4f70-8d5b-1da7f3cfe717EnglishJisc Publications RouterFrontiers Media2024Pasculli, GBusan, PJackson, ESAlm, PADe Gregorio, DMaguire, GAGoodwin, GMGobbi, GErritzoe, DCarhart-Harris, RLDevelopmental stuttering (DS) is a neurodevelopmental speech-motor disorder characterized by symptoms such as blocks, repetitions, and prolongations. Persistent DS often has a significant negative impact on quality of life, and interventions for it have limited efficacy. Herein, we briefly review existing research on the neurophysiological underpinnings of DS -specifically, brain metabolic and default mode/social-cognitive networks (DMN/SCN) anomalies- arguing that psychedelic compounds might be considered and investigated (e.g., in randomized clinical trials) for treatment of DS. The neural background of DS is likely to be heterogeneous, and some contribution from genetically determinants of metabolic deficiencies in the basal ganglia and speech-motor cortical regions are thought to play a role in appearance of DS symptoms, which possibly results in a cascade of events contributing to impairments in speech-motor execution. In persistent DS, the difficulties of speech are often linked to a series of associated aspects such as social anxiety and social avoidance. In this context, the SCN and DMN (also influencing a series of fronto-parietal, somato-motor, and attentional networks) may have a role in worsening dysfluencies. Interestingly, brain metabolism and SCN/DMN connectivity can be modified by psychedelics, which have been shown to improve clinical evidence of some psychiatric conditions (e.g., depression, post-traumatic stress disorder, etc.) associated with psychological constructs such as rumination and social anxiety, which also tend to be present in persistent DS. To date, while there have been no controlled trials on the effects of psychedelics in DS, anecdotal evidence suggests that these agents may have beneficial effects on stuttering and its associated characteristics. We suggest that psychedelics warrant investigation in DS.
spellingShingle Pasculli, G
Busan, P
Jackson, ES
Alm, PA
De Gregorio, D
Maguire, GA
Goodwin, GM
Gobbi, G
Erritzoe, D
Carhart-Harris, RL
Psychedelics in developmental stuttering to modulate brain functioning: a new therapeutic perspective?
title Psychedelics in developmental stuttering to modulate brain functioning: a new therapeutic perspective?
title_full Psychedelics in developmental stuttering to modulate brain functioning: a new therapeutic perspective?
title_fullStr Psychedelics in developmental stuttering to modulate brain functioning: a new therapeutic perspective?
title_full_unstemmed Psychedelics in developmental stuttering to modulate brain functioning: a new therapeutic perspective?
title_short Psychedelics in developmental stuttering to modulate brain functioning: a new therapeutic perspective?
title_sort psychedelics in developmental stuttering to modulate brain functioning a new therapeutic perspective
work_keys_str_mv AT pascullig psychedelicsindevelopmentalstutteringtomodulatebrainfunctioninganewtherapeuticperspective
AT busanp psychedelicsindevelopmentalstutteringtomodulatebrainfunctioninganewtherapeuticperspective
AT jacksones psychedelicsindevelopmentalstutteringtomodulatebrainfunctioninganewtherapeuticperspective
AT almpa psychedelicsindevelopmentalstutteringtomodulatebrainfunctioninganewtherapeuticperspective
AT degregoriod psychedelicsindevelopmentalstutteringtomodulatebrainfunctioninganewtherapeuticperspective
AT maguirega psychedelicsindevelopmentalstutteringtomodulatebrainfunctioninganewtherapeuticperspective
AT goodwingm psychedelicsindevelopmentalstutteringtomodulatebrainfunctioninganewtherapeuticperspective
AT gobbig psychedelicsindevelopmentalstutteringtomodulatebrainfunctioninganewtherapeuticperspective
AT erritzoed psychedelicsindevelopmentalstutteringtomodulatebrainfunctioninganewtherapeuticperspective
AT carhartharrisrl psychedelicsindevelopmentalstutteringtomodulatebrainfunctioninganewtherapeuticperspective